These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38648390)

  • 1. Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
    Fujita M; Nagashima K; Shimazu M; Suzuki M; Tauchi I; Sakuma M; Yamamoto S; Hanaoka H; Shozu M; Tsuruoka N; Kasai T; Hata A
    Int J Cancer; 2024 Sep; 155(5):905-915. PubMed ID: 38648390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study.
    Gottschlich A; Hong Q; Gondara L; Alam MS; Cook DA; Martin RE; Lee M; Melnikow J; Peacock S; Proctor L; Stuart G; Franco EL; Krajden M; Smith LW; Ogilvie GS
    Cancer Epidemiol Biomarkers Prev; 2024 Jul; 33(7):904-911. PubMed ID: 38773687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial.
    Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B
    BMC Cancer; 2018 Mar; 18(1):273. PubMed ID: 29523108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
    Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study.
    Aarnio R; Östensson E; Olovsson M; Gustavsson I; Gyllensten U
    BMC Cancer; 2020 Jul; 20(1):645. PubMed ID: 32660432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women.
    Morisada T; Teramoto K; Takano H; Sakamoto I; Nishio H; Iwata T; Hashi A; Katoh R; Okamoto A; Sasaki H; Nakatani E; Teramukai S; Aoki D
    Cancer Epidemiol; 2017 Oct; 50(Pt A):60-67. PubMed ID: 28818742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
    Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
    Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
    BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
    Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
    BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
    Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
    Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.
    El-Zein M; Bouten S; Louvanto K; Gilbert L; Gotlieb W; Hemmings R; Behr MA; Franco EL;
    Gynecol Oncol; 2018 Jun; 149(3):491-497. PubMed ID: 29678360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.